Filing Analysis
Rallybio Corporation announced the termination of its merger agreement with Candid Therapeutics, Inc. after Candid entered into an alternative agreement with UCB S.A. Rallybio is entitled to receive a $50 million termination fee plus expense reimbursements as a result of the deal's collapse.
Red Flags
- Failure of a previously announced strategic merger and reorganization.
- Withdrawal of a registration statement (Form S-4) indicating a halt to the planned capital structure changes.
Key Facts
- The Merger Agreement with Candid Therapeutics, originally dated March 1, 2026, was terminated on May 3, 2026.
- Candid Therapeutics terminated the deal to pursue a 'Permitted Alternative Agreement' with UCB S.A.
- Rallybio will receive a $50,000,000 Parent Termination Fee.
- Rallybio, Candid, and UCB entered into a Waiver on May 1, 2026, to facilitate the termination and release of claims.
- Rallybio intends to withdraw its Form S-4 registration statement previously filed for the merger.
Rallybio Corporation announced the immediate departure of its Chief Medical Officer, Steven Ryder, M.D., effective March 31, 2026. This departure occurs in the context of the company's pending merger with Candid Therapeutics, Inc., which was previously announced on March 1, 2026.
Red Flags
- Immediate departure of a key clinical executive (CMO) during a critical merger transition period.
Key Facts
- Steven Ryder, M.D., served as Chief Medical Officer since January 2019.
- Departure is effective immediately as of March 31, 2026.
- Dr. Ryder will receive severance payments for termination 'without cause' as per his employment agreement.
- Upon closing of the merger with Candid Therapeutics, Dr. Ryder will receive enhanced 'change of control' severance benefits.
- Equity awards will remain outstanding and eligible to vest according to the Merger Agreement, exercisable for 90 days post-closing.
Rallybio Corp has entered into a definitive merger agreement with Candid Therapeutics in a reverse merger transaction that will result in Rallybio shareholders owning only 3.65% of the combined company. The deal includes a concurrent financing of approximately $505.5 million and will result in a complete change of management and a corporate name change to Candid Therapeutics, Inc.
Red Flags
- Extreme dilution for existing Rallybio shareholders (96.35% total dilution).
- Mandatory reverse stock split required to maintain listing and facilitate the merger.
- Total turnover of the executive team and board of directors.
- The transaction is heavily contingent on a large-scale concurrent financing ($200M minimum).
Key Facts
- Rallybio equityholders will own approximately 3.65% of the combined company post-merger.
- Candid Therapeutics is valued at $750 million, while Rallybio is valued at $47.5 million (assuming $37.5 million in net cash).
- A concurrent financing is expected to raise $505.5 million, with a $200 million minimum required for closing.
- Ken Song, MD (Candid CEO) will become the CEO of the combined entity; all current Rallybio officers and directors will resign.
- The agreement necessitates a reverse stock split and a name change to 'Candid Therapeutics, Inc.'
- Candid may be required to pay a termination fee of up to $50 million under specific circumstances, while Rallybio's termination fee is $1.425 million.